Shares of Pfizer (PFE) were essentially flat in 2015, but the pharmaceutical giant’s decision in November to buy Allergan in a deal worth $160 billion made huge waves. Andrew McNair, president of Swan Capital, said there is more to his bullish call on Pfizer than the company’s bid to slash its U.S. tax bill. 'It is a great story that they dropped their overall corporate tax by almost 6 percent, but I think the real story is that with potential interest rate hikes on the way, it won’t have a major impact on drug companies,' said McNair. McNair is also bullish on Charles Schwab (SCHW) which saw its stock rise 17 percent last year. He said he likes the moat Schwab has built around its business in the form of $2 trillion in assets. Also, he said a significant move up in interest rates will help the discount broker because of its floating rate exposure. TheStreet's Gregg Greenberg has details from Wall Street.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.